These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35123433)

  • 21. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
    Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
    Tam C; Kuss B; Opat S; Boulos J; Marlton P
    Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
    Hoy SM
    Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.
    Russell A; Yaraskavitch M; Fok D; Chhibber S; Street L; Korngut L
    J Neuromuscul Dis; 2017; 4(3):251-257. PubMed ID: 28869483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Novak J; Strugov V; Gill D; Gribben JG; Kwei K; Dai S; Hsu E; Dean JP; Flinn IW
    Haematologica; 2022 Sep; 107(9):2108-2120. PubMed ID: 35021599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
    Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
    Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
    Goede V; Fischer K; Engelke A; Schlag R; Lepretre S; Montero LF; Montillo M; Fegan C; Asikanius E; Humphrey K; Fingerle-Rowson G; Hallek M
    Leukemia; 2015 Jul; 29(7):1602-4. PubMed ID: 25634683
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
    Woyach JA; Ruppert AS; Rai K; Lin TS; Geyer S; Kolitz J; Appelbaum FR; Tallman MS; Belch AR; Morrison VA; Larson RA; Byrd JC
    J Clin Oncol; 2013 Feb; 31(4):440-7. PubMed ID: 23233702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia.
    Mabed M; Aref S; Fouda M; El-Sharawy S
    Leuk Lymphoma; 2004 Oct; 45(10):2029-35. PubMed ID: 15370247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
    Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
    Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
    Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
    Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
    Offner F; Robak T; Janssens A; Govind Babu K; Kloczko J; Grosicki S; Mayer J; Panagiotidis P; Schuh A; Pettitt A; Montillo M; Werner O; Vincent G; Khanna S; Hillmen P
    Br J Haematol; 2020 Sep; 190(5):736-740. PubMed ID: 32236950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
    Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and management of obinutuzumab-associated toxicities: Australian experience.
    Snowden A; Hayden I; Dixon J; Gregory G
    Int J Nurs Pract; 2015 Dec; 21 Suppl 3():15-27. PubMed ID: 26681665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
    Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
    Robak T; Burger JA; Tedeschi A; Barr PM; Owen C; Bairey O; Hillmen P; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre SE; Quach H; Gaidano G; Maslyak Z; Stevens DA; Moreno C; Gill DS; Flinn IW; Gribben JG; Mokatrin A; Cheng M; Styles L; James DF; Kipps TJ; Ghia P
    Am J Hematol; 2018 Nov; 93(11):1402-1410. PubMed ID: 30129285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.